ArticleEuropean journal of neurology2025
Clinical and Genetic Reassessment in Patients With Clinically Diagnosed Hereditary Polyneuropathy.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Delayed Genetic Diagnosis of a Rare Presentation of Overlapping Peripheral Myelin Protein 22 (PMP22) Neuropathies.Cureus · 2026Article
- Hereditary Polyneuropathies in the Era of Precision Medicine: Genetic Complexity and Emerging Strategies.Genes · 2026Review
- Clinical and Genetic Reassessment in Patients With Clinically Diagnosed Hereditary Polyneuropathy.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundHereditary polyneuropathy is a disabling condition with a genetic aetiology. However, genetic confirmation is not always attainable. This study aimed to assess the diagnostic clarification rate achieved through reassessment, including whole genome sequencing (WGS), in patients without confirmed genetic diagnoses.
methodsWe conducted a cross-sectional study using diagnosis codes to identify patients with hereditary polyneuropathy at a specialized neuromuscular center. Clinically diagnosed patients without genetic confirmation were invited to participate. They underwent neurological examination, composite scoring, extensive blood testing, and WGS. Based on the reassessment, patients were stratified into three groups: (1) genetic findings, (2) non-genetic aetiologies, and (3) no identified aetiology.
resultsWe screened 386 patient records; 66 patients were eligible, and 44 were included. Mean age at inclusion was 52.7 years, and mean age at symptom onset was 31.2 years. Reassessment identified six non-genetic etiologies, including treatable causes such as disc protrusion, systemic lupus, and chronic inflammatory demyelinating polyneuropathy. A relevant genetic variant was identified in 13 out of the 44 patients, yielding a genetic clarification rate of 30%. The most frequent genetic variant was the homozygous c.757del variant in SORD, found exclusively in patients with axonal neuropathy and teenage onset.
conclusionsReassessment clarified the diagnosis in 44% of clinically diagnosed patients with hereditary polyneuropathy (30% genetic, 14% non-genetic), underscoring the potential of reassessment in improving diagnostic precision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.